| SAE Ref.: | | | / | | | | | | |
|-----------|--|--|---|--|--|--|--|--|--|
|-----------|--|--|---|--|--|--|--|--|--|





| Sa | AE FORM |
|--|-------------------------------------|
| To be complete | ed by the site (PART 1) |
| | |
| SITE DETAILS | |
| Site Name: | Name of PI: |
| | |
| | |
| | |
| PARTICIPANT DETAILS | |
| Trial No.: Sex: Male | e Female |
| Participants Initials: Participan | t Partial / / / / / / / |
| DoB: | |
| REPORT TYPE (use BCTU allocated unique SAE number if t | his is a follow-up or final report) |
| | |
| Initial Report: | |
| Follow-up Report: Please insert unique SAE number | r/ |
| Final Poport: | |
| Final Report: Please insert unique SAE number | |
| | |
| EVENT INFORMATION | |
| | |
| | |
| Signs and Symptoms: | |
| | |
| | |
| | |
| EVENT DIAGNOSIS | |
| | |
| | |
| Diagnosis: | |
| | |

CALIBRE SAE FORM

EudraCT No.: 2018-002488-24

v3.0, 8th November 2021

| SAE Ref.: / | | | CONFIDENTIAL WHEN COMPLETE |
|--|------|------------------|------------------------------------|
| Event Severity: Mild Modera | te 🗌 | Seve | re |
| | | | |
| SERIOUSNESS OF EVENT | | | |
| Seriousness of event | No | Yes | Details |
| (please provide a response to each question) | | | |
| Death: | | | Date of death: DD / MMM / YYYY |
| | | | Cause of death: |
| | | | |
| Life threatening event: | | | |
| In-patient hospitalisation or prolongation of | | | Initial |
| existing hospitalisation: | | | Prolonged |
| | | | Date of discharge: DD / MMM / YYYY |
| Persistent or significant disability/incapacity: | | | |
| Congenital anomaly or birth defect: | | | |
| Other medical reason for reporting? | | | Please specify: |
| | | | |
| | | | |
| DETAILS OF EVENT | | | |
| Date of Onset: DD / MMM / YYYY | / | Date Be | came Serious: DD / MMM / YYYY |
| Date Site Became Aware: DD / MMM / YYYY | / | Date res | solved: DD / MMM / YYYY |
| | | OR tick i | if ongoing |

CALIBRE SAE FORM

EudraCT No.: 2018-002488-24

| SAE Ref.: | | | / | | | | | CONFIDENTIAL WHEN COMPLETE |
|-----------|--|--|---|--|--|--|--|----------------------------|
|-----------|--|--|---|--|--|--|--|----------------------------|

| TRIAL INTERVE | ENTION SUMMARY | | | | | | |
|------------------------|---|-------------|---------------|-------------------------|--|---------------------------|--|
| | Il trial interventions being receiv | ed when the | e SAE started | | | | |
| Intervention | Intervention Received (Last date of last dose) | Route | Dose | Intervention Start Date | Action Taken 1=None 2=Intervention Stopped 3=Intervention Delayed 4=Intervention Reduced | Intervention Stopped Date | Causality Assessment 1=Unrelated 2=Unlikely to be related 3=Possibly related 4=Probably related 5=Definitely related |
| Carvedilol | DD/MMM/YYYY | Oral | | DD/MMM/YYYY | | DD/MMM/YYYY | |
| Variceal band ligation | DD/MMM/YYYY | N/A | N/A | DD/MMM/YYYY | | DD/MMM/YYYY | |
| (This must be ι | ssment undertaken by: undertaken by a medically qualifi delegated the task) | ed doctor | | | | | |

CALIBRE SAE FORM EudraCT No.: 2018-002488-24

| SAE Ref.:// | | | CONFIDENTIAL WHEN COMPLETE |
|--|-----------|-----|----------------------------|
| TRIAL TREATMENT | | | |
| Where drug interventions (IMP) have bee | n stopped | | |
| Did the event abate on stopping drug? | No | Yes | Not applicable |
| If yes please provide details: | | | |
| Did the event reappear after introduction of drug? | No | Yes | Not applicable |
| | | | |

CALIBRE SAE FORM EudraCT No.: 2018-002488-24

If yes please provide details:

v3.0, 8th November 2021

| SAE Ref.: | | | CONFIDENTIAL WHEN COMPLETE |
|-----------|--|--|----------------------------|
|-----------|--|--|----------------------------|

| CONCOMITANT MED | ICATIONS | | | | | |
|------------------------|-------------------------------------|--|-----------------------------------|-----|-------|-------------------------------|
| Has the participant ta | ken any other drugs whi | ich <u>may interact</u> with the inte | rvention or influence the SAE? No | | Yes | If yes, please complete below |
| Drug Name | Route 1=Oral 2=IV | Dose (including units and frequency) | Start Date | Ong | oing? | Stop Date (if relevant) |
| | 3=Subcutaneous 4=Other (specify) | | | No | Yes | |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |
| | | | DD/MMM/YYYY | | | DD/MMM/YYYY |

CALIBRE SAE FORM

EudraCT No.: 2018-002488-24

| SAE Ref.: // | | CONFIDENTIAL | WHEN COMPLETE |
|--|------------------------------------|-----------------------|----------------|
| RELEVANT MEDICAL HISTORY (provi | de narrative if relevant to diagno | sis) | |
| Please provide a narrative if relevant are relevant (where investigations of number only). | <u> </u> | | |
| | | | |
| | | | |
| | | | |
| UNRELATED EVENT | | | |
| If the event is unrelated, please provide details of an alternative explanation for the event: | | | |
| | | | |
| DETAILS OF PERSON REPORTING | | | |
| Name of person reporting: | Job title of person reporting: | | Date reported: |
| | | | DD/MMM/YYYY |
| Signature of person reporting: (must appear on delegation log) . | | Date of signature: | DD/MMM/YYYY |
| Signature of PI: | | Date of PI signature: | DD/MMM/YYYY |

Please return this form to the CALIBRE Trial Office at Birmingham Clinical Trials Unit

CALIBRE SAE FORM

EudraCT No.: 2018-002488-24

| SAE Ref.: | | / | | | CONFIDENTIAL WHEN COMPLETE |
|-----------|--|---|--|--|----------------------------|
| SAE Ref.: | | / | | | CONFIDENTIAL WHEN COMPLETE |

| | To be completed by the Ch | ief Investigat | or or named delegate (PART 2) | | | |
|--|--|----------------|---|--|--|--|
| Re | view of Causality | | Assessment of Expectedness This column should only be completed if causal | | | |
| Intervention | Review of Causality 1=Unrelated 2=Unlikely to be related 3=Possibly related 4=Probably related 5=Definitely related | Dose | relationship is classified as 3, 4 or 5 (possibly, probably or definitely related). The expectedness assessment must be made with reference to the reference safety information (RSI). | | | |
| Carvedilol | | | Expected | | | |
| Variceal band ligation | | N/A | Unexpected | | | |
| | | | | | | |
| CTCAE category: Please refer to coded referen | nce list below. | CTCAE ' | Term: | | | |
| | | | | | | |
| Coded Reference List | | | | | | |

| Commo | n Terminology Criteria for Adverse Events (CTCAE Coded | List) | |
|-------|--|-------|--|
| Code | Category | Code | Category |
| 1 | Blood and lymphatic system disorders | 14 | Metabolism and nutrition disorders |
| 2 | Cardiac disorders | 15 | Musculoskeletal and connective tissue disorders |
| 3 | Congenital, familial and genetic disorders | 16 | Neoplasms benign, malignant and unspecified (incl cysts and polyps |
| 4 | Ear and labyrinth disorders | 17 | Nervous system disorders |
| 5 | Endocrine disorders | 18 | Pregnancy, puerperium and perinatal conditions |
| 6 | Eye disorders | 19 | Psychiatric disorders |
| 7 | Gastrointestinal disorders | 20 | Renal and urinary disorders |
| 8 | General disorders and administration site conditions | 21 | Reproductive system and breast disorders |
| 9 | Hepatobiliary disorders | 22 | Respiratory, thoracic and mediastinal disorders |
| 10 | Immune system disorders | 23 | Skin and subcutaneous tissue disorders |
| 11 | Infections and infestations | 24 | Social circumstances |
| 12 | Injury, poisoning and procedural complications | 25 | Surgical and medical procedures |
| 13 | Investigations | 26 | Vascular disorders |

| SIGNATURES | | | | |
|--|------------------------------|-----------------------------------|--|--|
| In signing this form the CI or delegate confirms the Causality and Expectedness of the event | | | | |
| Name of CI or delegate: | Signature of CI or delegate: | Date of CI or delegate signature: | | |
| | | DD/MMM/YYYY | | |

CALIBRE SAE FORM EudraCT No.: 2018-002488-24 v3.0, 8th November 2021

| SAE Ref.: | | CONFIDENTIA | L WHEN COMPLETE | | |
|------------------------|---------------------------------------|---------------------------------------|-----------------|--|--|
| FOR BCTU USE ONLY | | | | | |
| SAE Reference Number: | | | | | |
| Participants randomise | d to the carvedilol arm: | | | | |
| Event Categorised as: | SAE SAR | | | | |
| | SUSAR (fatal or life threatening) | Date reported to CA, REC and Sponsor: | DD/MMM/YYYY | | |
| | SUSAR (non-fatal or life threatening) | Date reported to CA, REC and Sponsor: | DD/MMM/YYYY | | |
| Participants randomise | d to the variceal band ligation arm: | | | | |
| | SAE | | | | |

Date reported to REC

and Sponsor:

DD/MMM/YYYY

Completed by:

Event Categorised as:

| lame: | Signature: | Date of signature: |
|-------|------------|--------------------|
| | | DD / MMM / YYYY |

Serious related and unexpected event

CALIBRE SAE FORM EudraCT No.: 2018-002488-24